{"disease":{"id":"various-advanced-cancer","name":"various advanced cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03143153","title":"A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":970,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT02632409","title":"An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":709,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT02488759","title":"An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":578,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT02387996","title":"A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT03130959","title":"A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":166,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}